Skip to main content
SpringerLink
Log in

Pathological Diagnosis of Cholangiocarcinoma

  • Chapter
  • First Online:
Diagnosis and Management of Cholangiocarcinoma

Abstract

Cholangiocarcinoma has a heterogeneous histologic appearance due to the various anatomic sites it can arise from, ranging from small intrahepatic interlobular bile ducts to the common bile duct. Using common sampling techniques including needle core biopsy, exfoliative brushing, and aspiration cytology, the diagnosis can be established using morphologic criteria, immunohistochemistry, ancillary cytogenetics, and molecular-based techniques. Pathologic staging is reported according to the site of tumor origin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AFP:

Alpha-fetoprotein

BilIN:

Biliary intraepithelial neoplasia

CEA:

Carcinoembryonic antigen

CT:

Computed tomography

DIA:

Digital image analysis

ERCP:

Endoscopic retrograde cholangiopancreatography

EUS:

Endoscopic ultrasound

FISH:

Fluorescent in situ hybridization

FNA:

Fine needle aspiration

HCC:

Hepatocellular carcinoma

IMP3:

Insulin-like growth factor-I mRNA binding protein-3

IPNB:

Intraductal papillary neoplasms of bile ducts

KRAS:

Kristen rat sarcoma

MCN:

Mucinous cystic neoplasm

NGS:

Next-generation sequencing

PSC:

Primary sclerosing cholangitis

pVHL:

von Hippel-Lindau protein

TFF1:

Trefoil factor 1

References

  1. Brugge W, Dewitt J, Klapman JB, Ashfaq R, Shidham V, Chhieng D, et al. Techniques for cytologic sampling of pancreatic and bile duct lesions. Diagn Cytopathol. 2014;42(4):333–7. https://doi.org/10.1002/dc.23096.

    Article  PubMed  Google Scholar 

  2. Kitajima Y, Ohara H, Nakazawa T, Ando T, Hayashi K, Takada H, et al. Usefulness of transpapillary bile duct brushing cytology and forceps biopsy for improved diagnosis in patients with biliary strictures. J Gastroenterol Hepatol. 2007;22(10):1615–20. https://doi.org/10.1111/j.1440-1746.2007.05037.x.

    Article  PubMed  Google Scholar 

  3. Jung GS, Huh JD, Lee SU, Han BH, Chang HK, Cho YD. Bile duct: analysis of percutaneous transluminal forceps biopsy in 130 patients suspected of having malignant biliary obstruction. Radiology. 2002;224(3):725–30. https://doi.org/10.1148/radiol.2242011501.

    Article  PubMed  Google Scholar 

  4. Gonzalez-Aguirre A, Covey AM, Brown KT, Brody LA, Boas FE, Sofocleous CT, et al. Comparison of biliary brush biopsy and fine needle biopsy in the diagnosis of biliary strictures. Minim Invasive Ther Allied Technol. 2018;27(5):278–83. https://doi.org/10.1080/13645706.2018.1427597.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc. 2015;81(1):168–76. https://doi.org/10.1016/j.gie.2014.09.017.

    Article  PubMed  Google Scholar 

  6. Vadmal MS, Byrne-Semmelmeier S, Smilari TF, Hajdu SI. Biliary tract brush cytology. Acta Cytol. 2000;44(4):533–8. https://doi.org/10.1159/000328525.

    Article  CAS  PubMed  Google Scholar 

  7. Onoyama T, Matsumoto K, Takeda Y, Kawata S, Kurumi H, Koda H, et al. Endoscopic ultrasonography-guided fine needle aspiration for extrahepatic cholangiocarcinoma: a safe tissue sampling modality. J Clin Med. 2019;8(4):417. https://doi.org/10.3390/jcm8040417.

    Article  CAS  PubMed Central  Google Scholar 

  8. Jo JH, Cho CM, Jun JH, Chung MJ, Kim TH, Seo DW, et al. Same-session endoscopic ultrasound-guided fine needle aspiration and endoscopic retrograde cholangiopancreatography-based tissue sampling in suspected malignant biliary obstruction: a multicenter experience. J Gastroenterol Hepatol. 2019;34(4):799–805. https://doi.org/10.1111/jgh.14528.

    Article  CAS  PubMed  Google Scholar 

  9. Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, et al. A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol. 2015;39(12):1730–41. https://doi.org/10.1097/PAS.0000000000000533.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Martins EB, Fleming KA, Garrido MC, Hine KR, Chapman RW. Superficial thrombophlebitis, dysplasia, and cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1994;107(2):537–42. https://doi.org/10.1016/0016-5085(94)90182-1.

    Article  CAS  PubMed  Google Scholar 

  11. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol. 2010;34(1):27–34. https://doi.org/10.1097/PAS.0b013e3181bc96f9.

    Article  PubMed  Google Scholar 

  12. Bergquist A, Glaumann H, Stal P, Wang GS, Broome U. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. J Intern Med. 2001;249(1):69–75. https://doi.org/10.1046/j.1365-2796.2001.00775.x.

    Article  CAS  PubMed  Google Scholar 

  13. Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2001;34(3):360–5. https://doi.org/10.1016/s0168-8278(00)00034-9.

    Article  CAS  PubMed  Google Scholar 

  14. Kerr SE, Barr Fritcher EG, Campion MB, Voss JS, Kipp BR, Halling KC, et al. Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma. Hum Pathol. 2014;45(9):1797–804. https://doi.org/10.1016/j.humpath.2014.05.008.

    Article  PubMed  Google Scholar 

  15. Hughes NR, Pairojkul C, Royce SG, Clouston A, Bhathal PS. Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes. J Clin Pathol. 2006;59(10):1073–8. https://doi.org/10.1136/jcp.2005.033712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rocha FG, Lee H, Katabi N, RP DM, Fong Y, D’Angelica MI, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology. 2012;56(4):1352–60. https://doi.org/10.1002/hep.25786.

    Article  CAS  PubMed  Google Scholar 

  17. Yeh TS, Tseng JH, Chen TC, Liu NJ, Chiu CT, Jan YY, et al. Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions. Hepatology. 2005;42(3):657–64. https://doi.org/10.1002/hep.20837.

    Article  PubMed  Google Scholar 

  18. Nakanuma Y, Sato Y, Ojima H, Kanai Y, Aishima S, Yamamoto M, et al. Clinicopathological characterization of so-called “cholangiocarcinoma with intraductal papillary growth” with respect to “intraductal papillary neoplasm of bile duct (IPNB)”. Int J Clin Exp Pathol. 2014;7(6):3112–22.

    PubMed  PubMed Central  Google Scholar 

  19. Fukumura Y, Nakanuma Y, Kakuda Y, Takase M, Yao T. Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes. Virchows Arch. 2017;471(1):65–76. https://doi.org/10.1007/s00428-017-2144-9.

    Article  PubMed  Google Scholar 

  20. Nakanuma Y, Jang KT, Fukushima N, Furukawa T, Hong SM, Kim H, et al. A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage. J Hepatobiliary Pancreat Sci. 2018;25(3):181–7. https://doi.org/10.1002/jhbp.532.

    Article  PubMed  Google Scholar 

  21. Yang CY, Huang WJ, Tsai JH, Cheng A, Chen CC, Hsu HP, et al. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct. Mod Pathol. 2019;32(11):1637–45. https://doi.org/10.1038/s41379-019-0306-9.

    Article  CAS  PubMed  Google Scholar 

  22. Schlitter AM, Jang KT, Kloppel G, Saka B, Hong SM, Choi H, et al. Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol. 2015;28(9):1249–64. https://doi.org/10.1038/modpathol.2015.61.

    Article  CAS  PubMed  Google Scholar 

  23. Quigley B, Reid MD, Pehlivanoglu B, Squires MH 3rd, Maithel S, Xue Y, et al. Hepatobiliary mucinous cystic neoplasms with ovarian type stroma (so-called “hepatobiliary cystadenoma/cystadenocarcinoma”): clinicopathologic analysis of 36 cases illustrates rarity of carcinomatous change. Am J Surg Pathol. 2018;42(1):95–102. https://doi.org/10.1097/PAS.0000000000000963.

    Article  PubMed  Google Scholar 

  24. Tumours of the gallbladder and extrahepatic bile ducts. In: Klimstra DS LA, Paradis V, Shirmacher P, editors. WHO classification of tumours: digestive system tumours. 5th ed: IARC; 2019. p. 265–94.

    Google Scholar 

  25. Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104(4):426–33. https://doi.org/10.1002/bjs.10452.

    Article  CAS  PubMed  Google Scholar 

  26. Mao K, Liu J, Sun J, Zhang J, Chen J, Pawlik TM, et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol. 2016;31(2):417–26. https://doi.org/10.1111/jgh.13072.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Andrianello S, Paiella S, Allegrini V, Ramera M, Pulvirenti A, Malleo G, et al. Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up. Langenbeck's Arch Surg. 2015;400(5):623–8. https://doi.org/10.1007/s00423-015-1320-0.

    Article  Google Scholar 

  28. Zhang XF, Squires MH 3rd, Bagante F, Ethun CG, Salem A, Weber SM, et al. The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma. Ann Surg Oncol. 2018;25(5):1140–9. https://doi.org/10.1245/s10434-018-6382-0.

    Article  PubMed  Google Scholar 

  29. Otsuka S, Ebata T, Yokoyama Y, Mizuno T, Tsukahara T, Shimoyama Y, et al. Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma. Br J Surg. 2019;106(6):774–82. https://doi.org/10.1002/bjs.11125.

    Article  CAS  PubMed  Google Scholar 

  30. Shinohara K, Ebata T, Shimoyama Y, Mizuno T, Yokoyama Y, Yamaguchi J, et al. A study on radial margin status in resected perihilar cholangiocarcinoma. Ann Surg. 2019; https://doi.org/10.1097/SLA.0000000000003305.

  31. Wellner UF, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today. 2017;47(3):271–9. https://doi.org/10.1007/s00595-016-1362-0.

    Article  CAS  PubMed  Google Scholar 

  32. Chuang SC, Lee KT, Tsai KB, Sheen PC, Nagai E, Mizumoto K, et al. Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg. 2004;28(10):995–1000. https://doi.org/10.1007/s00268-004-7447-8.

    Article  PubMed  Google Scholar 

  33. Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer. 2001;91(7):1332–41.

    Article  CAS  PubMed  Google Scholar 

  34. Nakazawa T, Naitoh I, Hayashi K, Okumura F, Miyabe K, Yoshida M, et al. Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification. J Gastroenterol. 2012;47(1):79–87. https://doi.org/10.1007/s00535-011-0465-z.

    Article  CAS  PubMed  Google Scholar 

  35. Nakazawa T, Naitoh I, Hayashi K, Miyabe K, Simizu S, Joh T. Diagnosis of IgG4-related sclerosing cholangitis. World J Gastroenterol. 2013;19(43):7661–70. https://doi.org/10.3748/wjg.v19.i43.7661.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Deshpande V, Sainani NI, Chung RT, Pratt DS, Mentha G, Rubbia-Brandt L, et al. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol. 2009;22(10):1287–95. https://doi.org/10.1038/modpathol.2009.94.

    Article  CAS  PubMed  Google Scholar 

  37. Tumours of the liver and intrahepatic bile ducts. In: Paradis V FM, Park YN, Schirmacher P, editors. WHO classification of tumours: digestive system tumours. 5th ed: IARC; 2019. p. 217–64.

    Google Scholar 

  38. Sigel CS, Drill E, Zhou Y, Basturk O, Askan G, Pak LM, et al. Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns. Am J Surg Pathol. 2018;42(10):1334–45. https://doi.org/10.1097/PAS.0000000000001118.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenbergen W, Verslype C, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012;55(6):1876–88. https://doi.org/10.1002/hep.25595.

    Article  CAS  PubMed  Google Scholar 

  40. Nakanuma Y, Sato Y, Ikeda H, Harada K, Kobayashi M, Sano K, et al. Intrahepatic cholangiocarcinoma with predominant “ductal plate malformation” pattern: a new subtype. Am J Surg Pathol. 2012;36(11):1629–35. https://doi.org/10.1097/PAS.0b013e31826e0249.

    Article  PubMed  Google Scholar 

  41. Balitzer D, Joseph NM, Ferrell L, Shafizadeh N, Jain D, Zhang X, et al. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Mod Pathol. 2019;32(10):1486–94. https://doi.org/10.1038/s41379-019-0290-0.

    Article  CAS  PubMed  Google Scholar 

  42. Tsokos CG, Krings G, Yilmaz F, Ferrell LD, Gill RM. Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma. Hum Pathol. 2016;57:61–7. https://doi.org/10.1016/j.humpath.2016.06.019.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Sasaki M, Matsubara T, Kakuda Y, Sato Y, Nakanuma Y. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma. Am J Surg Pathol. 2014;38(3):364–9. https://doi.org/10.1097/PAS.0000000000000125.

    Article  PubMed  Google Scholar 

  44. Hatano M, Ojima H, Masugi Y, Tsujikawa H, Hiraoka N, Kanai Y, et al. Steatotic and nonsteatotic scirrhous hepatocellular carcinomas reveal distinct clinicopathological features. Hum Pathol. 2019;86:222–32. https://doi.org/10.1016/j.humpath.2018.11.024.

    Article  PubMed  Google Scholar 

  45. Okamura N, Yoshida M, Shibuya A, Sugiura H, Okayasu I, Ohbu M. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int. 2005;55(11):724–31. https://doi.org/10.1111/j.1440-1827.2005.01891.x.

    Article  CAS  PubMed  Google Scholar 

  46. Brackett DG, Neyaz A, Arora K, Masia R, Mattia A, Zukerberg L, et al. Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. J Clin Pathol. 2020;73(1):23–9. https://doi.org/10.1136/jclinpath-2019-206055.

    Article  CAS  PubMed  Google Scholar 

  47. Brunt EM, Paradis V, Sempoux C, Theise ND. Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. Hepat Oncol. 2015;2(3):255–73. https://doi.org/10.2217/hep.15.8.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68(1):113–26. https://doi.org/10.1002/hep.29789.

    Article  PubMed  Google Scholar 

  49. Lee SH, Lee JS, Na GH, You YK, Kim DG. Immunohistochemical markers for hepatocellular carcinoma prognosis after liver resection and liver transplantation. Clin Transpl. 2017;31(1):e12852. https://doi.org/10.1111/ctr.12852.

    Article  CAS  Google Scholar 

  50. Geramizadeh B, Seirfar N. Diagnostic value of arginase-1 and glypican-3 in differential diagnosis of hepatocellular carcinoma, cholangiocarcinoma and metastatic carcinoma of liver. Hepat Mon. 2015;15(7):e30336. https://doi.org/10.5812/hepatmon30336v2.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol. 2012;7:149. https://doi.org/10.1186/1746-1596-7-149.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33(12):1175–81. https://doi.org/10.1053/hupa.2002.130104.

    Article  PubMed  Google Scholar 

  53. Surrey LF, Frank R, Zhang PJ, Furth EE. TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels. Am J Surg Pathol. 2014;38(2):224–7. https://doi.org/10.1097/PAS.0000000000000138.

    Article  PubMed  Google Scholar 

  54. Lino-Silva LS, Salcedo-Hernandez RA, Garcia-Gomez MA, Ruiz-Garcia EB, Aguilar-Romero JM, Dominguez-Rodriguez JA, et al. Thyroid transcription factor-1 expression in adenocarcinomas of the bile duct. Int J Surg Pathol. 2016;24(1):24–8. https://doi.org/10.1177/1066896915603121.

    Article  CAS  PubMed  Google Scholar 

  55. Conner JR, Hornick JL. Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry. Adv Anat Pathol. 2015;22(3):149–67. https://doi.org/10.1097/PAP.0000000000000069.

    Article  CAS  PubMed  Google Scholar 

  56. Tang H, Wang Z, Lv W, Meng X. The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma. Intractable Rare Dis Res. 2018;7(2):106–11. https://doi.org/10.5582/irdr.2018.01047.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Liu F, Gao Z, Shen D, Zhao H, Wang C, Ye Y, et al. Significance of SATB2 expression in colon cancer and its differential diagnosis in digestive tract adenocarcinoma and ovarian primary and metastatic carcinoma. Pathol Res Pract. 2019;215(7):152430. https://doi.org/10.1016/j.prp.2019.04.022.

    Article  CAS  PubMed  Google Scholar 

  58. Nash JW, Morrison C, Frankel WL. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver. Arch Pathol Lab Med. 2003;127(12):1591–5. https://doi.org/10.1043/1543-2165(2003)127<1591:TUOERA>2.0.CO;2.

    Article  CAS  PubMed  Google Scholar 

  59. Wei S, Said-Al-Naief N, Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol. 2009;17(5):393–402. https://doi.org/10.1097/PAI.0b013e31819faa07.

    Article  CAS  PubMed  Google Scholar 

  60. Agostini-Vulaj D, Bratton LE, Dunne RF, JMM C, Zhou Z, Findeis-Hosey JJ, et al. Incidence and significance of GATA3 positivity in pancreatic ductal adenocarcinoma and cholangiocarcinoma. Appl Immunohistochem Mol Morphol. 2019; https://doi.org/10.1097/PAI.0000000000000764.

  61. Rhee H, Ko JE, Chung T, Jee BA, Kwon SM, Nahm JH, et al. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver Int. 2018;38(1):113–24. https://doi.org/10.1111/liv.13492.

    Article  CAS  PubMed  Google Scholar 

  62. Akita M, Fujikura K, Ajiki T, Fukumoto T, Otani K, Azuma T, et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol. 2017;30(7):986–97. https://doi.org/10.1038/modpathol.2017.22.

    Article  CAS  PubMed  Google Scholar 

  63. Nasir A, Lehrke HD, Mounajjed T, Said S, Zhang L, Yasir S, et al. Albumin in situ hybridization can be positive in adenocarcinomas and other tumors from diverse sites. Am J Clin Pathol. 2019;152(2):190–9. https://doi.org/10.1093/ajcp/aqz032.

    Article  CAS  PubMed  Google Scholar 

  64. Askan G, Deshpande V, Klimstra DS, Adsay V, Sigel C, Shia J, et al. Expression of markers of hepatocellular differentiation in pancreatic acinar cell neoplasms: a potential diagnostic pitfall. Am J Clin Pathol. 2016;146(2):163–9. https://doi.org/10.1093/ajcp/aqw096.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Lin F, Shi J, Wang HL, Ma XJ, Monroe R, Luo Y, et al. Detection of albumin expression by RNA in situ hybridization is a sensitive and specific method for identification of hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Am J Clin Pathol. 2018;150(1):58–64. https://doi.org/10.1093/ajcp/aqy030.

    Article  CAS  PubMed  Google Scholar 

  66. Retracted. Histopathology. 2019; https://doi.org/10.1111/his.14046.

  67. Baron TH, Harewood GC, Rumalla A, Pochron NL, Stadheim LM, Gores GJ, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol. 2004;2(3):214–9. https://doi.org/10.1016/s1542-3565(04)00006-0.

    Article  PubMed  Google Scholar 

  68. Cohen MB, Wittchow RJ, Johlin FC, Bottles K, Raab SS. Brush cytology of the extrahepatic biliary tract: comparison of cytologic features of adenocarcinoma and benign biliary strictures. Mod Pathol. 1995;8(5):498–502.

    CAS  PubMed  Google Scholar 

  69. Renshaw AA, Madge R, Jiroutek M, Granter SR. Bile duct brushing cytology: statistical analysis of proposed diagnostic criteria. Am J Clin Pathol. 1998;110(5):635–40. https://doi.org/10.1093/ajcp/110.5.635.

    Article  CAS  PubMed  Google Scholar 

  70. Avadhani V, Hacihasanoglu E, Memis B, Pehlivanoglu B, Hanley KZ, Krishnamurti U, et al. Cytologic predictors of malignancy in bile duct brushings: a multi-reviewer analysis of 60 cases. Mod Pathol. 2017;30(9):1273–86. https://doi.org/10.1038/modpathol.2017.51.

    Article  CAS  PubMed  Google Scholar 

  71. Heath JE, Goicochea LB, Staats PN. Biliary stent-related alterations can be distinguished from adenocarcinoma on bile duct brushings using a limited number of cytologic features. J Am Soc Cytopathol. 2015;4(5):282–9. https://doi.org/10.1016/j.jasc.2015.06.006.

    Article  PubMed  Google Scholar 

  72. Trikudanathan G, Navaneethan U, Njei B, Vargo JJ, Parsi MA. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79(5):783–9. https://doi.org/10.1016/j.gie.2013.09.015.

    Article  PubMed  Google Scholar 

  73. Goyal A, Sharaiha RZ, Alperstein SA, Siddiqui MT. Cytologic diagnosis of adenocarcinoma on bile duct brushings in the presence of stent associated changes: a retrospective analysis. Diagn Cytopathol. 2018;46(10):826–32. https://doi.org/10.1002/dc.24052.

    Article  PubMed  Google Scholar 

  74. Pitman MB, Layfield LJ. The papanicolaou society of cytopathology system for reporting pancreaticobiliary cytology. Cham: Springer; 2015.

    Book  Google Scholar 

  75. Layfield L. Role of ancillary techniques in biliary cytopathology specimens. Acta Cytol. 2020;64(1–2):175–81. https://doi.org/10.1159/000498976.

    Article  CAS  PubMed  Google Scholar 

  76. Gonda TA, Glick MP, Sethi A, Poneros JM, Palmas W, Iqbal S, et al. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc. 2012;75(1):74–9. https://doi.org/10.1016/j.gie.2011.08.022.

    Article  PubMed  Google Scholar 

  77. Barr Fritcher EG, Kipp BR, Halling KC, Clayton AC. FISHing for pancreatobiliary tract malignancy in endoscopic brushings enhances the sensitivity of routine cytology. Cytopathology. 2014;25(5):288–301. https://doi.org/10.1111/cyt.12170.

    Article  CAS  PubMed  Google Scholar 

  78. Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99(9):1675–81. https://doi.org/10.1111/j.1572-0241.2004.30281.x.

    Article  PubMed  Google Scholar 

  79. Brooks C, Gausman V, Kokoy-Mondragon C, Munot K, Amin SP, Desai A, et al. Role of fluorescent in situ hybridization, cholangioscopic biopsies, and EUS-FNA in the evaluation of biliary strictures. Dig Dis Sci. 2018;63(3):636–44. https://doi.org/10.1007/s10620-018-4906-x.

    Article  CAS  PubMed  Google Scholar 

  80. von Seth E, Ouchterlony H, Dobra K, Hjerpe A, Arnelo U, Haas S, et al. Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis. Liver Int. 2019;39(2):382–8. https://doi.org/10.1111/liv.14007.

    Article  Google Scholar 

  81. Kushnir VM, Mullady DK, Das K, Lang G, Hollander TG, Murad FM, et al. The diagnostic yield of malignancy comparing cytology, fish, and molecular analysis of cell free cytology brush supernatant in patients with biliary strictures undergoing endoscopic retrograde cholangiography (ERC): a prospective study. J Clin Gastroenterol. 2019;53(9):686–92. https://doi.org/10.1097/MCG.0000000000001118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–61. https://doi.org/10.1158/1078-0432.CCR-18-0078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn. 2010;12(6):780–6. https://doi.org/10.2353/jmoldx.2010.100016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Sturm PD, Rauws EA, Hruban RH, Caspers E, Ramsoekh TB, Huibregtse K, et al. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res. 1999;5(3):629–35.

    CAS  PubMed  Google Scholar 

  85. Schlitter AM, Born D, Bettstetter M, Specht K, Kim-Fuchs C, Riener MO, et al. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol. 2014;27(1):73–86. https://doi.org/10.1038/modpathol.2013.112.

    Article  CAS  PubMed  Google Scholar 

  86. Abraham SC, Lee JH, Hruban RH, Argani P, Furth EE, Wu TT. Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. Hum Pathol. 2003;34(9):902–10. https://doi.org/10.1016/s0046-8177(03)00337-x.

    Article  CAS  PubMed  Google Scholar 

  87. Dudley JC, Zheng Z, McDonald T, Le LP D-SD, Borger D, et al. Next-generation sequencing and fluorescence in situ hybridization have comparable performance characteristics in the analysis of pancreaticobiliary brushings for malignancy. J Mol Diagn. 2016;18(1):124–30. https://doi.org/10.1016/j.jmoldx.2015.08.002.

    Article  CAS  PubMed  Google Scholar 

  88. Harbhajanka A, Michael CW, Janaki N, Gokozan HN, Wasman J, Bomeisl P, et al. Tiny but mighty: use of next generation sequencing on discarded cytocentrifuged bile duct brushing specimens to increase sensitivity of cytological diagnosis. Modern Pathol Off J U S Can Acad Pathol Inc. 2020; https://doi.org/10.1038/s41379-020-0577-1.

  89. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–3. https://doi.org/10.1038/ng.2813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18(11):2780–94. https://doi.org/10.1016/j.celrep.2017.02.033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–65. https://doi.org/10.21037/jgo.2019.03.10.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Wang T, Drill E, Vakiani E, Pak LM, Boerner T, Askan G, et al. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma. Hum Pathol. 2019;91:19–25. https://doi.org/10.1016/j.humpath.2019.05.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010;41(9):1210–9. https://doi.org/10.1016/j.humpath.2010.01.014.

    Article  CAS  PubMed  Google Scholar 

  94. Tokumitsu T, Sato Y, Yamashita A, Moriguchi-Goto S, Kondo K, Nanashima A, et al. Immunocytochemistry for Claudin-18 and Maspin in biliary brushing cytology increases the accuracy of diagnosing pancreatobiliary malignancies. Cytopathology. 2017;28(2):116–21. https://doi.org/10.1111/cyt.12368.

    Article  CAS  PubMed  Google Scholar 

  95. Chen L, Huang K, Himmelfarb EA, Zhai J, Lai JP, Lin F, et al. Diagnostic value of maspin in distinguishing adenocarcinoma from benign biliary epithelium on endoscopic bile duct biopsy. Hum Pathol. 2015;46(11):1647–54. https://doi.org/10.1016/j.humpath.2015.07.005.

    Article  CAS  PubMed  Google Scholar 

  96. Kanzawa M, Sanuki T, Onodera M, Fujikura K, Itoh T, Zen Y. Double immunostaining for maspin and p53 on cell blocks increases the diagnostic value of biliary brushing cytology. Pathol Int. 2017;67(2):91–8. https://doi.org/10.1111/pin.12505.

    Article  CAS  PubMed  Google Scholar 

  97. Ieni A, Todaro P, Crino SF, Barresi V, Tuccari G. Endoscopic ultrasound-guided fine-needle aspiration cytology in pancreaticobiliary carcinomas: diagnostic efficacy of cell-block immunocytochemistry. Hepatobiliary Pancreat Dis Int. 2015;14(3):305–12. https://doi.org/10.1016/s1499-3872(15)60367-8.

    Article  PubMed  Google Scholar 

  98. Tretiakova M, Antic T, Westerhoff M, Mueller J, Himmelfarb EA, Wang HL, et al. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions. Am J Surg Pathol. 2012;36(1):101–8. https://doi.org/10.1097/PAS.0b013e31822fbc95.

    Article  PubMed  Google Scholar 

  99. Jang SI, Kwon NH, Lim BJ, Nahm JH, Park JS, Kang CM, et al. New staining method using methionyl-tRNA synthetase 1 antibody for brushing cytology of bile duct cancer. Gastrointest Endosc. 2019; https://doi.org/10.1016/j.gie.2019.12.017.

  100. Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

    Google Scholar 

  101. Fritcher EG, Kipp BR, Halling KC, Oberg TN, Bryant SC, Tarrell RF, et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology. 2009;136(7):2180–6. https://doi.org/10.1053/j.gastro.2009.02.040.

    Article  PubMed  Google Scholar 

  102. Huang P, Zhang H, Zhang XF, Zhang X, Lyu W, Fan Z. Evaluation of intraductal ultrasonography, endoscopic brush cytology and K-ras, P53 gene mutation in the early diagnosis of malignant bile duct stricture. Chin Med J. 2015;128(14):1887–92. https://doi.org/10.4103/0366-6999.160508.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Kaura K, Sawas T, Bazerbachi F, Storm AC, Martin JA, Gores GJ, et al. Cholangioscopy biopsies improve detection of cholangiocarcinoma when combined with cytology and FISH, but not in patients with PSC. Dig Dis Sci. 2019; https://doi.org/10.1007/s10620-019-05866-2.

  104. Gonda TA, Viterbo D, Gausman V, Kipp C, Sethi A, Poneros JM, et al. Mutation profile and fluorescence in situ hybridization analyses increase detection of malignancies in biliary strictures. Clin Gastroenterol Hepatol. 2017;15(6):913–9 e1. https://doi.org/10.1016/j.cgh.2016.12.013.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Carlie Sigel

  2. Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada

    Tao Wang

Authors
  1. Carlie Sigel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlie Sigel .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA, USA

    James H. Tabibian

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sigel, C., Wang, T. (2021). Pathological Diagnosis of Cholangiocarcinoma. In: Tabibian, J.H. (eds) Diagnosis and Management of Cholangiocarcinoma. Springer, Cham. https://doi.org/10.1007/978-3-030-70936-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70936-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70935-8

  • Online ISBN: 978-3-030-70936-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation